 |  |
 |
- Luminex Corporation Reports First Quarter 2012 Results
- Luminex Corporation Receives CE Mark for Revolutionary Newborn Screening Platform
- Luminex Corporation Expands Life Science and Biodefense Groups
- Luminex Corporation First Quarter Earnings Release Scheduled for April 30, 2012
- Luminex and Bio-Rad Extend Their Global Sales and Distribution Agreement to 2023
- Luminex Corporation Receives Deloitte Technology Fast 500(TM) Award
- Luminex Corporation Joins Forces with the National Marrow Donor Program - Be The Match®
Clinical Diagnostics
Improving patient care through novel multiplexed molecular diagnostic solution
Infectious Disease
Human Genetics
Personalized Medicine
Human Leukocyte Antigens
Life Science Research
Advancing basic research and scientific discoveries through the power of multiplexing
Gene Expression
Protein Analysis
Drug Discovery
Oncology
Specialty Markets
Developing innovative detection platforms and assays for public health preparedness and food safety
Biodefense
Environmental Diagnostics
Luminex Corporation develops, manufactures and markets innovative biological testing technologies with applications throughout the clinical diagnostic and life science industries. The company’s open-architecture xMAP® and xTAG® Technologies enable large numbers of biological tests (bioassays) to be conducted and analyzed quickly, cost-effectively and accurately. Systems using xMAP technology perform discrete bioassays on the surface of color-coded beads known as microspheres, which are then read in a compact analyzer.
